Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19

NACompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 13, 2020

Primary Completion Date

July 31, 2021

Study Completion Date

March 22, 2022

Conditions
COVID-19
Interventions
DEVICE

Auricular percutaneous neurostimulation

The BRIDGE/PENFS device manufactured by Key Electronics, consists of a battery activated generator and wire harness that connects to the generator. Four leads are also attached to the generator, each with a sterile 2 mm, titanium needle. The BRIDGE device settings are standardized and deliver 3.2 volts with alternating frequencies (1 ms pulses of 1 Hz and 10 Hz) every 2 s. This stimulation targets central pain pathways through branches of cranial nerves V, VII, IX, and X, which innervate the external ear. The PENFS device generator has a battery life of 5 days and delivers almost continuous stimulations throughout the 120 hours.

Trial Locations (1)

91342

Olive View-UCLA Medical Center, Sylmar

All Listed Sponsors
lead

Olive View-UCLA Education & Research Institute

OTHER

NCT04514627 - Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19 | Biotech Hunter | Biotech Hunter